Want to see TMDX full AI Analyst Report?
TMDX Stock Chart & Stats
$72.26
$1.28(1.77%)
At close: 4:00 PM EDT
$72.26
$1.28(1.77%)
Day’s Range― - ―
52-Week Range$60.11 - $156.00
Previous CloseN/A
Volume216.03K
Average Volume (3M)959.09K
Market Cap
$3.10B
Enterprise Value$3.10K
Total Cash (Recent Filing)$472.68M
Total Debt (Recent Filing)$867.72M
Price to Earnings (P/E)19.7
Beta1.23
Next Earnings
Nov 04, 2026EPS Estimate
0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.42
Shares Outstanding34,675,144
10 Day Avg. Volume841,515
30 Day Avg. Volume959,090
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)8.74
Price to Sales (P/S)6.83
P/FCF Ratio30.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$94.22Price Target Upside30.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)1.55
Revenue Forecast (FY)$743.10M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Recurring ConsumablesTransMedics shows durable top-line momentum with record quarterly revenue and strong product/service growth. The business model ties recurring disposable components and case services to each transplant, driving predictable per‑case revenue and supporting sustained growth as installed base and utilization expand.
High Gross MarginGross margins near 60% indicate favorable unit economics for the OCS platform and consumables. That structural margin provides room to fund R&D and international rollout, supports attractive incremental profit per case, and underpins long‑term scalability even while operating expenses rise.
Strong Liquidity PositionA sizable cash balance gives the company flexibility to self‑fund strategic programs (OCS Kidney, Gen3, logistics), absorb near‑term dilution from PAD consolidation, and manage working capital. This reduces refinancing risk and supports multi‑year investment in commercialization and regulatory milestones.
Bears Say
Rising LeverageLeverage has increased notably, reducing balance sheet flexibility and magnifying downside if margins slip. Higher debt raises interest sensitivity and constrains capital allocation; with meaningful interest expense expected, elevated leverage could pressure cash flow available for growth or M&A.
Near-term Margin PressureManagement has lowered near‑term operating margin targets as it front‑loads R&D and strategic programs. Sustained margin compression would erode free cash flow conversion and limit reinvestment capacity, making execution on long‑range revenue targets more dependent on timely payoff from these investments.
Execution Risk On Key Programs & InternationalRevenue and margin upside rely on clinical/regulatory milestones (ENHANCE, DENOVO, Gen3) and scaling international logistics. Delays or slower commercialization would defer expected revenue streams, prolong investment drag, and make near‑term profitability and European expansion outcomes uncertain.
TransMedics Group News
TMDX FAQ
What was Transmedics Group’s price range in the past 12 months?
Transmedics Group lowest stock price was $60.10 and its highest was $156.00 in the past 12 months.
What is Transmedics Group’s market cap?
Transmedics Group’s market cap is $3.10B.
When is Transmedics Group’s upcoming earnings report date?
Transmedics Group’s upcoming earnings report date is Nov 04, 2026 which is in 82 days.
How were Transmedics Group’s earnings last quarter?
Transmedics Group released its earnings results on Aug 04, 2026. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.496 by -$0.056.
Is Transmedics Group overvalued?
According to Wall Street analysts Transmedics Group’s price is currently Undervalued.
Does Transmedics Group pay dividends?
Transmedics Group does not currently pay dividends.
What is Transmedics Group’s EPS estimate?
Transmedics Group’s EPS estimate is 0.3.
How many shares outstanding does Transmedics Group have?
Transmedics Group has 34,675,144 shares outstanding.
What happened to Transmedics Group’s price movement after its last earnings report?
Transmedics Group reported an EPS of $0.44 in its last earnings report, missing expectations of $0.496. Following the earnings report the stock price went down -5.276%.
Which hedge fund is a major shareholder of Transmedics Group?
Currently, no hedge funds are holding shares in TMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TransMedics Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$94.22 (30.39% Upside)
$94.22 (30.39% Upside)
Blogger Sentiment
Bullish
TMDX Sentiment 81%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 691.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
64.44%
Trailing 12-Months
Company Description
Transmedics Group
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
TMDX Company Deck
TMDX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and commercial picture: record revenue, strong product and service growth (notably liver and logistics), improved sequential gross margin, robust cash balance, and raised revenue guidance. At the same time, the company is investing heavily in strategic initiatives (OCS Kidney, Gen 3.0, ENHANCE, DENOVO, European logistics/PAD) which is elevating R&D and operating expenses, tempering near-term operating margin and introducing execution and timing risk (IDE approvals, PAD integration and international reimbursement). Overall, the fundamentals and long-term growth roadmap are strong, but near-term profitability will be impacted by deliberate, front-loaded investments and some timing uncertainties.View all TMDX earnings summariesTMDX Stock 12 Month Forecast
Average Price Target
$94.22
▲(30.39% Upside)
Technical Analysis
Ownership Overview
3.60% Insiders
42.62% Mutual Funds
8.64% Other Institutional Investors
17.37% Public Companies and Individual Investors